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Abstract
Background: ORFV attenuated live vaccines have been the main prophylactic measure against contagious
ecthyma in sheep and goats in the last decades, which play an important role in preventing the outbreak of the
disease. However, the available vaccines do not induce lasting immunity in sheep and goats. On the other hand,
variation in the terminal genome of Orf virus vaccine strains during cell culture adaptation may affect the efficacy
of a vaccine. Currently, there are no more effective antiviral treatments available for contagious ecthyma.
Results: We constructed three eukaryotic expression vectors pcDNA3.1-ORFV011, pcDNA3.1-ORFV059 and
pcDNA3.1-ORFV011/ORFV059 and tested their immunogenicity in mouse model. High level expression of the
recombinant proteins ORFV011, ORFV059 and ORFV011/ORFV059 was confirmed by western blotting analysis and
indirect fluorescence antibody (IFA) tests. The ORFV-specific antibody titers and serum IgG1/IgG2a titers, the
proliferation of lymphocytes and ORFV-specific cytokines (IL-2, IL-4, IL-6, IFN-g, and TNF-a) were examined to
evaluate the immune responses of the vaccinated mice. We found that mice inoculated with pcDNA3.1-ORFV 011/
ORFV059 had significantly stronger immunological responses than those inoculated with pcDNA3.1-ORFV011,
pcDNA3.1-ORFV059, or pcDNA3.1-ORFV011 plus pcDNA3.1-ORFV059. Compared to other vaccine plasmids
immunized groups, pcDNA3.1-ORFV011/ORFV059 immunized group enhances immunogenicity.
Conclusions: We concluded that DNA vaccine pcDNA3.1-ORFV011/ORFV059 expressing ORFV011 and ORFV059
chemeric-proteins can significantly improve the potency of DNA vaccination and could be served as more effective
and safe approach for new vaccines against ORFV.
Background
Orf virus (ORFV) is the prototype species of the Para-
poxvirus genus, which causes contagious ecthyma in
sheep and goats. The disease is also known as Orf, con-
tagious pustular dermatitis, infectious labial dermatitis,
scabby mouth, and sore mouth. The disease, which is
distributed worldwide and endemic in most sheep and/
or goat-raising countries, is characterized by proliferative
and self-limiting lesions around the muzzle and lips
(scabby mouth) of infected animals, and sometimes also
affects the gums and tongue, especially in young lambs
[1,2]. The disease has a very high morbidity. Though
mortality is low and usually does not exceed ten per-
cent, mortality rates of up to 10% and 93% have been
reported in lambs and kids [3-5]. The disease is fre-
quently severe enough to create substantial welfare pro-
blems in flocks [6]. This, in turn, has an economic
impact on sheep farmers due to the accompanying
decreases in production.
In recent years, reports of severe Orf outbreaks in
flocks have been gradually increased [7-10]. In addition,
am i l df o r mo ft h ed i s e a s eh as been described in wild
ruminants and in humans, in which is characterized by
self-limiting, painful pustular lesions on the hands and
fingers [11,12]. Several ORFV attenuated live vaccines
have been used worldwide since 1981 and form the
main prophylactic measure against contagious ecthyma
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attenuated live vaccines are less effective at preventing
the disease at present. It mainly due to the available vac-
cines do not induce lasting immunity in sheep and the
rapid changes in the genomes of Orf virus vaccine
strains during cell culture adaptation, particularly invol-
ving the ends of viral genome [14].
The host immune response to ORFV has been exten-
sively studied, yet many aspects of the complex host-
virus interactions remain unclear. Several studies have
demonstrated that the major envelop proteins of ORFV
could induce a strong immune response [15,16]. As a
major immunogenic protein, the ORFV011 protein can
induce a strong antibody response by stimulating lym-
phocytes derived from draining lymph nodes [17]. In
addition, the potential of the ORFV059 protein to act as
an antigen in subunit vaccines against antigenically iden-
tical Orf viral strains has been indicated. Furthermore, it
seems to be responsible for induction of neutralizing
antibodies in the host, and plays an important role in
the viral cycle [15,18]. Considering the immunogenicity
of the ORFV 011 and ORFV059 proteins, it is possible
that the chimeric expression of the ORFV011 and
ORFV059 proteins could induce stronger immune
responses.
In this study, we assembled DNA vaccine plasmids
expressing the two major immunodominant proteins
(ORFV011 and ORFV059) of the Orf virus, individually
and simultaneously. The expression of the recombinant
proteins in vitro was investigated by western blotting
analysis and indirect fluorescence antibody (IFA) tests.
The levels of protective humoral and cellular immune
responses induced by the recombinant ORFV DNA vac-
cines were investigated in a mouse model.
Methods
Virus and cells
A newly identified fatal strain of Orf virus was isolated
from scab specimens collected from skin lesions of a 6-
week-old small-tailed Han sheep affected with Orf virus
in November 2008 in the Jilin province of China [9].
Primary ovine fetal turbinate (OFTu) cells were main-
tained in minimal essential medium (MEM) (Hyclone)
supplemented with 10% fetal bovine serum (FBS)
(Hyclone), 2 mM L-glutamine, 100 U of penicillin/ml,
100 μg of streptomycin/ml, and 20 μg of nystatin/ml.
The virus was propagated in OFTu cells. For virus har-
vest, cell culture supernata n tf r o mi n f e c t e dc e l l sw e r e
collected when approximately 90% of the culture
showed cytopathic effects (CPE). After three freeze-thaw
cycles, the supernatant was then cleared at 500 × g for
1 0m i na t4 ° Ca n ds t o r e da t- 8 0 ° C .T h ev i r u sw a sp u r i -
fied by sucrose gradient centrifugation. Infectivity titre
was assayed by the plaque method in OFTu cell culture
and calculated as plaque forming units (PFU).
Construction of the expression plasmids
All expression plasmids were constructed using
pcDNA3.1(+) (Invitrogen, USA) as the vector. The two
primer sets used for PCR amplification are specific for
either ORFV 011 (forward primer: 5’-TATAG-
GATCCGCCATGT GGCCGTTCTCCTCCATC-3’;
reverse primer: 5’-CCGCTCGAGTTAATT-
TATTGGCTTGCAG-3’) (restriction sites in bold) or
ORFV059 (forward primer: 5’-CAAGCTTGCCAC-
CATGGATCCACCCGAAATC-3’; reverse primer: 5’-
CGAATTCTCACACGATGGCCGTGACC-3’) (restric-
tion sites in bold). The plasmids pMDT-ORFV011 and
pMDT-ORFV059, containing the complete ORFV011
and ORFV059 genes of the ORFV Jilin province strain,
respectively, have been described previously [9]. The
DNA vaccine constructs pcDNA3.1-ORFV011 and
pcDNA3.1-ORFV059 expressing ORFV011 protein and
ORFV059 protein individually were generated by sub-
cloning the ORFV011 and ORFV059 genes into
pcDNA3.1 (+), respectively. To construct the ORFV011/
ORFV059 chimeric expression plasmid, the two primer
sets mentioned above were modified by inserting a lin-
ker structure which encoded a (G4S)2 polypeptide in the
5’ t e r m i n io ft h eO R F V 0 1 1r e v e r s ep r i m e ra n dt h e
ORFV059 forward primer. In addition, the stop codon
of the ORFV011 reverse primer and the promotor of
the ORFV059 forward primer were deleted. The modi-
fied primer sequences were as follows: ORFV011 (for-
ward primer: 5’-TATAGGATCCGCCATGTGGCCGT
TCTCCTCCATC-3’; reverse primer:5’-AGAGCCTC
CGCCACCGGATCCACCGCCACCATTTATTGGCTT
GCAGAA-3’) (linker structure in italic) and ORFV059
(forward primer: 5’- GGTGGCGGTGGATCCGGT
GGCGGAGGCTCTGAAATCACGGGCTACATAATC-
3’; reverse primer: 5’-CGAATTCTCACACGATGGC
CGTGACC-3’) (linker structure in italic). The coding
sequence of the ORFV011 gene without the stop codon
was amplified from pMDT-ORFV011 by PCR, using
ORFV011 modified primers, and the gene for ORFV059
without the promoter was amplified from pMDT-
ORFV059 using ORFV059 modified primers. PCR pro-
ducts, including the ORFV011 and ORFV059 genes
obtained by overlap PCR, were cloned into a pcDNA3.1
(+) vector, generating pcDNA3.1-ORFV 011/ORFV059
plasmid. All recombinant plasmids (data not shown) were
confirmed by restriction digestion and sequence analysis.
Expression of recombinant proteins in vitro
OFTu cells were cultured in MEM containing 10% fetal
bovine serum (FBS) in a 5% CO2 incubator at 37°C.
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plasmid (control) or pcDNA3.1-ORFV011, pcDNA3.1-
ORFV059 and pcDNA3.1-ORFV 011/ORFV059 recom-
binant vaccine plasmids. Briefly, OFTu cells were grown
to 80% confluence in 6-well culture plates (Costar,
Corning Incorporated, USA) and transfected with 8-10
μg of recombinant plasmids for each well, respectively.
After 48 h post-transfection, cell lysates collected from
pcDNA3.1(+) vector plasmid-transfected or pcDNA3.1-
ORFV011, pcDNA3.1-ORFV059 and pcDNA3.1-
ORFV059/ORFV011 recombinant vaccine plasmids-
transfected OFTu cells were analyzed by SDS-PAGE and
Western blot, respectively.
To further study the subcellular localization of target
protein, the pcDNA3.1(+) vector plasmid-transfected or
pcDNA3.1-ORFV011, pcDNA3.1-ORFV059 and
pcDNA3.1-ORFV011/ORFV059 recombinant vaccine
plasmids-transfected OFTu cells were subjected to an
IFA test employing rabbit anti-ORFV polyclonal anti-
body (kindly provided by the Jilin Institute for Veterin-
ary Research, diluted at 1:100). The secondary antibody
used was FITC-conjugated goat anti-rabbit IgG (H + L)
(1:500 dilution in PBS). After immunostaining, the nor-
mal control and transfected cells were observed under a
fluorescent microscope.
Immunization
Large-scale preparations of DNA vaccine plasmids were
obtained using alkaline lysis. Sixty 6-8-week-old female
Balb/c mice (purchased from the Laboratory Animal
Center of Jilin University in China) were used for
experiments in accordance with the guidelines for ani-
mal experimentation of Jilin University. The animals
were maintained under pathogen-free conditions, ran-
domly divided into six groups (ten mice per group), and
immunized by skin scarification [19] with one of the fol-
lowing formulations: (π) the A group was immunized
with PBS, (θ)t h eBg r o u pw i t h1 0 0μgp c D N A 3 . 1 ( + )
plasmids, (r) the C group with 100 μg pcDNA3.1-
ORFV011 plasmids, (s) the D group with 100 μg
pcDNA3.1-ORFV059 plasmids, (τ) the E group with 50
μg pcDNA3.1-ORFV011 plasmids plus 50 μg
pcDNA3.1-ORFV059 plasmids, and () the F group with
100 μg pcDNA3.1-ORFV011/ORFV059 plasmids. The
mice were boosted in the same manner on days 14 and
28. Blood samples were collected from the tail artery at
weeks 0, 1, 2, 3, 4, 5, 6, 7 and 8 post immunization. The
sera were inactivated at 56°C for 30 min and stored at
-80°C until assayed by ELISA (IgG at each time-points,
IgG1/IgG2a isotype at 1 week post the final boost
immunization, virus-neutralizing antibody at 2 weeks
post immunization). On day 10 after the final boost
immunization, 5 mice of each group were sacrificed by
cervical dislocation, and their splenocytes were isolated
for a lymphocyte proliferation assay and flow cytometry
assay.
ORFV-specific antibody titer assay
ORFV-specific antibody responses were determined
using an indirect ELISA, with the purified ORFV as the
antigen. Briefly, Costar High Binding 96-well plates
(eBioscience, San Diego, CA) were coated overnight at
4°C with 0.1 μg of purified ORFV diluted in 100 μlo f
0.1 M NaHCO3 buffer (pH 9.6). The plates were
blocked with PBS/0.1% Tween-20/2% BSA (150 μl/well)
for 1 h at 37°C. After washing three times with PBS/
0.1% Tween-20, sera were added in a dilution of 1:20 in
PBS/0.1% Tween-20/2% BSA. The plates were incubated
for 90 min at 37°C, washed three times, and then incu-
bated with 100 μl of horseradish-peroxidase (HRP)-con-
jugated goat anti-mouse IgG (Zhongshan Biotechnology
Company, Beijing, China) at a dilution of 1:5000 in PBS/
0.1% Tween-20/2% BSA for 1 h at 37°C. After three
washes, the presence of IgG was detected with 100 μlo f
TMB according to the manufacturer’s instructions. The
reaction was stopped by adding 50 μlo f2MH 2SO4.
The OD value was read at 450 nm. Results were
expressed as an antibody endpoint titer, determined
when the OD value is 3-fold greater than the back-
ground value obtained with a 1:20 dilution of serum
from PBS-injected mice. The purified ORFV antigen was
replaced with OFTu cell supernanant as a negative
control.
Immunoglobulin isotyping ELISA
In order to determine the IgG1 and IgG2a subtypes in
mice immunized with ORFV vaccine plasmids, purified
ORFV was diluted to optimal concentrations in 0.1 M
NaHCO3 buffer (pH 9.6), which was used as coating
antigen. Costar High Binding 96-well plates
(eBioscience, San Diego, CA) were coated with 0.1 μgo f
purified ORFV diluted in 100 μl of 0.1 M NaHCO3 buf-
fer (pH 9.6). The plates were blocked with PBS/0.1%
Tween-20/2% BSA (150 μl/well) for 1 h at 37°C. After
washing three times with PBS/0.1% Tween-20, the sera
were diluted at 1:20 in PBS/0.1% Tween-20. After a 1 h
incubation, the plates were washed with PBS/0.1%
T w e e n - 2 0a n dg o a ta n t im o u s eI g G 1 ,I g G 2 a( S i g m a
Chemical Co., SA Locus, Mo.) diluted to 1:1000 were
used to detect IgG1 and IgG2a subtypes, respectively.
After incubating for 60 min, the plates were washed
with PBS/0.1% Tween-20, and horseradish-peroxidase
(HRP)-conjugated rabbit anti-goat IgG (Zhongshan Bio-
technology Company, Beijing, China) diluted to 1:4000
in PBS/0.1% Tween-20 was added to each well. The
reaction was visualized after 1 h of incubation with
TMB. The reaction was stopped by adding 50 μlo f2M
H2SO4. The OD value was read at 450 nm. Results were
Zhao et al. Virology Journal 2011, 8:562
http://www.virologyj.com/content/8/1/562
Page 3 of 12expressed as an antibody endpoint titer, determined
when the OD value is 3-fold greater than the back-
ground value obtained with a 1:20 dilution of serum
from PBS-injected mice.
Determination of virus-neutralizing titers
To perform the virus neutralization assay, serum sam-
ples were diluted 1:5 in MEM medium and heat-acti-
vated for 30 min at 56°C. This 1:5 starting dilution of
inactivated sera was serially diluted two-fold in MEM
medium in 96-well flat bottom plates and incubated
with 0.1 μg of purified ORFV diluted in 50 μl MEM for
90 min at 37°C. All sera were run in triplicate. Subse-
quently, 100 μl of OFTu cell suspension were added to
each well at a concentration of 45,000 cells/well. The
plates were incubated for 5 days at 37°C in a 5% CO2
incubator. The neutralization titer of a serum is the
dilution at which 50% of the wells are protected against
virus infection. The titer is expressed as ND50 and cal-
culated using the Reed and Muench method.
Splenocyte preparations
Single-cell suspensions of spleens were prepared from
the immunized mice at day 10 post the final boost
immunization. Briefly, spleens from freshly killed mice
were disrupted by using monofilament nylon filters, and
the cells were collected and centrifuged at 500 × g for
20 min. The cell pellets were suspended in 10 ml RPMI
1640 and then centrifuged at 500 × g for 10 min at
room temperature. The cells were resuspended in RPMI
1640 supplemented with 10% FBS at a concentration of
1×1 0
7 cells/ml before the lymphocyte proliferation
assay and flow cytometry assay.
Cellular proliferation assay
Untreated splenocytes were cultured in RPMI 1640
medium with 10% fetal serum. The cells were suspended
in complete RPMI 1640 to achieve the concentration of
1×1 0
6 splenocytes/well. The primary incubation was at
37°C in a 5% CO2 incubator for 72 h, followed by addi-
tion of 10 μl MTT (5 mg/ml) per well and a secondary
incubation at 37°C in a 5% CO2 incubator for another 4
h. The microplates were centrifuged, the unreacted
MTT was removed, then 100 μld i m e t h y ls u l f o x i d e
(DMSO) was added per well to solubilize formazan. The
plates were then incubated for 10 min with shaking.
The absorbance of the plate was read using a 570 nm
filter within minutes following shaking. The treated cells
were cultured under the same conditions, but with the
addition of purified ORFV antigen (at a final concentra-
tion of 5 μg/ml) in complete RPMI 1640 medium. The
mitogen, Con A was added at 5 μg/ml concentration in
the positive control wells. The geometric means and
standard deviations for triplicate sets of samples were
calculated. Lymphocyte proliferation is expressed as a
stimulation index (SI), which is defined as the mean of
experimental data divided by the mean of the unstimu-
lated control [20,21].
Flow cytometry assay
In order to determine the changes of specific T cell sub-
sets in mice immunized with ORFV vaccine plasmids,
the flow cytometry assay were performed. 1 × 10
6 sple-
nocytes collected from the immunized mice at day 10
post the final boost immunization were suspended in
PBS and stained with FITC-conjugated anti-mouse CD3,
PE-Cy5-conjugated anti-mouse CD8, and PE-conjugated
anti-mouse CD4 for 30 min on ice. After three washes
with PBS, the cells were centrifuged at 500 × g for 10
min. The cells were suspended in 200 μlP B S .A tl e a s t
10,000 cells were analyzed per sample. The stained cells
were analyzed by a BD FACSAria flow cytometer, and
the data were analyzed with Cellquest V3.3 software.
ELISA assay
The production of ORFV-specific cytokines (IL-2, IL-4,
IL-6, IFN-g and TNF-a) was assessed by culturing sple-
nocytes (1 × 10
6 cells/ml) in triplicate with purified
ORFV antigen (5 μg/ml). Control stimuli included RPMI
1640 medium alone or ConA at 5 μg/ml. The superna-
tants were harvested after 72 h at 37°C in a 5% CO2 incu-
bator, filtered and stored at -20°C until assayed. The
presence of IL-2, IL-4, IL-6, IFN-g and TNF-a in mouse
splenocytes culture supernatants were determined by
commercial cytokines immunoassay kits (Dakewa Bio-
tech Company, Shenzhen, China) according to the manu-
facturer’s instructions. Supplied standards were used to
generate a standard curve. The detection limits of the
assay were 2.5 pg/ml, 3.0 pg/ml, 3.5 pg/ml, 2.0 pg/ml, 2.0
pg/ml for IL-2, IL-4, IL-6, IFN-g and TNF-a, respectively.
Statistical analysis
All data were analyzed using the statistical software pro-
gram Systat 10 (SPSS). The distribution of data was
determined using descriptive statistics. Data which were
not normally distributed were transformed by ranking.
Differences in ELISA titers were investigated using one-
way analysis of variance (ANOVA) performed on the
rank. The means of the rank-transformed variables were
compared using Tukey’s multiple comparison test.
Values of * P <0 . 0 5 ,* *P < 0.01 were considered statis-
tically significant.
Results
Expression of ORFV011 protein, ORFV059 protein and
ORFV011/ORFV059 chemeric-proteins in vitro
To confirm whether the pcDNA3.1-ORFV011,
pcDNA3.1-ORFV059 and pcDNA3.1-ORFV011/
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tein, ORFV 059 protein and ORFV011/ORFV059 chi-
meric-proteins in vitro, the pcDNA3.1-ORFV 011,
pcDNA3.1-ORFV059 and pcDNA3.1-ORFV011/
ORFV059 recombinant vaccine plasmids-transfected
OFTu cell lysates were analyzed by SDS-PAGE and
Western blot, respectively. A pcDNA3.1(+) vector was
used as negative control. Western blot analysis revealed
that ORFV011 protein, ORFV059 protein and
ORFV011/ORFV059 chimeric- proteins bands could be
detected in pcDNA3.1-ORFV011, pcDNA3.1-ORFV059
and pcDNA3.1-ORFV011/ORFV059 recombinant vac-
cine plasmids-transfected OFTu cell lysates (Figure 1,
Lanes 2, 4, 6), but no corresponding protein bands were
detected in the pcDNA3.1(+)-transfected cell lysates
(Figure 1, Lanes 1, 3, 5). Beta-actin was probed as an
internal control. In addition, the IFA tests on the
pcDNA3.1-ORFV011, pcDNA3.1-ORFV059 and
pcDNA3.1-ORFV011/ORFV059 vaccine plasmids-trans-
fected cells were performed in order to further identify
the expression of ORFV011 protein, ORFV059 protein
and ORFV011/ORFV059 chimeric-proteins and study
their subcellular localization. After 48 h post-transfec-
tion, the specific green fluorescence signal could be
detected in the cytoplasm of pcDNA3.1-ORFV011,
pcDNA3.1-ORFV059 and pcDNA3.1-ORFV011/
ORFV059-transfected cells, repectively (Figure 2c, d and
2e), but no fluorescence was found in untransfected
cells or pcDNA3.1(+)-transfected cell (Figure 2a and 2b).
Specific antibody immune responses of mice to ORFV in
different immunized groups
To determine the immunogenicity of pcDNA3.1-
ORFV011, pcDNA3.1-ORFV059, pcDNA3.1-ORFV011/
ORFV059 and pcDNA3.1-ORFV011 plus pcDNA3.1-
ORFV059 vaccine plasmids, four groups of the mice
were respectively immunized by skin scarification with
vaccine plasmids mentioned above. Two additional
groups received either pcDNA3.1(+) vector plasmids or
PBS. To investigate the humoral immune responses in
mice induced by different DNA vaccine plasmids, sera
from mice in groups (pcDNA3.1-ORFV011 group,
pcDNA3.1-ORFV059 group, pcDNA3.1-ORFV 011/
ORFV059 group, pcDNA3.1-ORFV011 plus pcDNA3.1-
ORFV059 group, pcDNA3.1(+) group and PBS group)
were collected weekly and anti-ORFV-IgG antibodies in
these sera were detected by ELISA. As shown in Figure
3, the levels of anti-ORFV-IgG antibodies were devel-
oped in different DNA vaccine plasmid- immunized
group. One week after the final boost immunization, the
level of anti-ORFV-IgG antibodies was higher in the
pcDNA3.1-ORFV011/ORFV059 immunized group than
any of the other groups tested (OD450 value: 0.829 ±
0.014, **P < 0.01). The levels of anti-ORFV-IgG antibo-
dies in both of pcDNA3.1-ORFV011 group and
pcDNA3.1-ORFV059 group were very nearly, but in the
pcDNA3.1-ORFV011 group increased slightly compared
with the pcDNA3.1-ORFV059 group (OD450 value:
0.579 ± 0.009 vs 0.518 ± 0.003, P > 0.05). The levels of
anti-ORFV-IgG antibodies was higher in the pcDNA3.1-
ORFV011/ORFV059 group than pcDNA3.1-ORFV011
plus pcDNA3.1-ORFV059 group (OD450 value: 0.829 ±
0.014 vs 0.687 ± 0.024, *P < 0.05). In addition, ORFV-
specific immunoglobulin G (IgG) subclasses 1 and 2a
were also detected 1 week after the final immunization
(Figure 4). In both pcDNA3.1 (+) plasmids and PBS
groups, the levels of IgG1 and IgG2a were fairly low.
However, the levels of anti-ORFV IgG1 and IgG2a in
DNA vaccine plasmids immunizations groups were
higher than control groups (including pcDNA3.1 (+)
group and PBS group). We further examined whether
there was any difference in the type of T helper
Figure 1 Western blot analysis of ORFV011 protein, ORFV059 protein and ORFV 011/ORFV 059 chemeric-proteins. OFTu cells were
transfected with pcDNA 3.1(+) plasmid (control) or pcDNA 3.1-ORFV 011, pcDNA 3.1-ORFV 059, pcDNA 3.1-ORFV 011/ORFV 059 vaccine plasmids,
respectively. After 48 h post-transfection, lysates collected from different vaccine plasmids-transfected OFTu cell were examined by SDS-PAGE
-Western blotting with rabbit anti-ORFV polyclonal antibody (kindly provided by the Jilin Institute for Veterinary Research, diluted at 1:100).
ORFV011 protein, ORFV059 protein and ORFV 011/ORFV059 chimeric-proteins bands could be detected in pcDNA3.1-ORFV011, pcDNA3.1-
ORFV059 and pcDNA3.1-ORFV011/ORFV059 recombinant vaccine plasmids-transfected OFTu cell lysates (Figure 1, Lanes 2, 4, 6), but no
corresponding protein bands were detected in the pcDNA3.1(+)-transfected cell lysates (Figure 1, Lanes 1, 3, 5). Lanes 2, 4, 6: OFTu cells
transfected with pcDNA 3.1-ORFV011, pcDNA 3.1-ORFV059 or pcDNA 3.1-ORFV011/ORFV059 vaccine plasmids, respectively. Lanes 1, 3, 5: OFTu
cells transfected with pcDNA 3.1(+) plasmid (control).
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ratio as a surrogate marker. Interestingly, the ratios of
IgG2a/IgG1 in mice receiving DNA vaccine plasmids
immunizations were more than 1, indicating that DNA
vaccine plasmid constructs induced predominantly a
Th1-type immune response after the final boost immu-
nization. In addition, the virus-neutralizing titers were
determined in sera pooled from immunized mice of dif-
ferent groups 2 weeks post immunization. As shown in
Figure 5, the neutralizing activity against ORFV was
detected at a high level in sera of mice immunized with
DNA vaccine plasmid constructs. The assay of virus-
neutralizing titers indicated a significant difference
between four vaccine plasmids groups (including
pcDNA3.1-ORFV011 group, pcDNA3.1-ORFV059
group, pcDNA3.1-ORFV011 plus pcDNA3.1-ORFV059
group and pcDNA3.1-ORFV011/ORFV059 group) and
control groups (including PBS and pcDNA3.1(+) group)
(**P < 0.01). Among the four vaccine plasmids groups,
the virus-neutralizing titer in the pcDNA3.1-ORFV011/
ORFV059 group was significantly higher than that of
pcDNA3.1-ORFV011 plus pcDNA3.1-ORFV059 group
(*P < 0.05).
Proliferation-inducing effect of splenocytes in different
immunized groups
The ability of ORFV DNA vaccine plasmids to mediate
spleen lymphocyte proliferation was measured by a
MTT colorimetric method. Representative results of a
proliferation study using prepared splenocytes of various
groups are shown in Figure 6. Compared to background
OD (SI = 0.281 ± 0.123), mice immunized with
pcDNA3.1-ORFV 011/ORFV 059 (F group) induced a
stronger proliferation response (**P < 0.01). The E
group, immunized with pcDNA3.1-ORFV 011 plus
pcDNA3.1-ORFV 059, also resulted displayed a higher
stimulation index (SI) than mice immunized with PBS,
pcDNA3.1 (+) and vaccine plasmid alone (pcDNA 3.1-
ORFV011 or pcDNA 3.1-ORFV059). However, the sti-
mulation index (SI) in pcDNA3.1-ORFV011/ORFV059
Figure 2 The intracellular location of ORFV011 protein, ORFV059 protein and ORFV 011/ORFV059 chemeric-proteins in transfected
OFTu cells. The OFTu cells were seeded in 6-well culture plates and un-transfected (Figure 2a) or transfected with pcDNA3.1(+) vector (Figure
2b), pcDNA3.1-ORFV011 plasmid (Figure 2c), pcDNA3.1-ORFV059 plasmid (Figure 2d) or pcDNA3.1-ORFV011/ORFV059 plasmid (Figure 2e) for 48
h. After 48 h post-transfection, the cells were fixed with 80% acetone for 10 min at -20°C, rehydrated in PBS, labeled with a rabbit anti-ORFV
polyclonal antibody, and washed three times with PBS. FITC-conjugated goat anti-rabbit IgG (H + L) (1:500 dilution in PBS) was added to the
OFTu cell mixtures for 30 min at room temperature, and the cells were washed and observed with a fluorescence microscopy. Magnification:
400 ×.
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ORFV011 plus pcDNA3.1-ORFV 059 group (P > 0.05),
and the stimulation index (SI) were no obvious differ-
ence between pcDNA3.1-ORFV011 group and
pcDNA3.1-ORFV059 group (P > 0.05).
Subsets of specific T lymphocyte cells
To examine whether or not immunized mice by skin
scarification developed an induced T-cell response
against ORFV, T lymphocyte cells from mice in groups
(pcDNA3.1-ORFV011 group, pcDNA3.1-ORFV059
group, pcDNA3.1-ORFV 011/ORFV059 group,
pcDNA3.1-ORFV 011 plus pcDNA3.1-ORFV group,
pcDNA3.1(+) group and PBS group) were respectively
enriched from the spleens 10 days after the final boost
immunization and cultured in RPMI 1640 medium. As
shown in Figure 7, the percentages of CD4
+ and CD8
+
cells in mice immunized with DNA vaccine plasmids
increased significantly compared to mice immunized
with the PBS and pcDNA3.1(+). The ratios of CD4
+/CD8
+ cells in mice immunized with vaccine plasmids
were higher than the control groups. These results
further indicate that the DNA vaccine constructs can
induce a T-cell response in mice and activate cell
immunity response.
ORFV-specific cytokine production in the splenocytes
culture supernatants
We also investigated the responsiveness of spleen cells
from immunized mice against ORFV. We determined
the levels of cytokines production (IFN-g,T N F - a,I L - 2 ,
IL-4 and IL-6) in the supernatant of splenocytes stimu-
lated with purified ORFV. Little levels of IFN-g,T N F - a
and IL-2 were observed in mice immunized with empty
vector or PBS. The levels of IFN-g, TNF-a and IL-2 pro-
duced by splenocytes immunized with ORFV DNA vac-
cine plasmids were significantly higher than that with
pcDNA3.1 (+) or PBS (**P < 0.01). The levels of Th2
type cytokines (IL-4 and IL-6) increased slightly in
ORFV DNA vaccine plasmids immunized mice com-
pared with pcDNA3.1 (+) or PBS immunized mice, but
the changes were not so dramatic(Figure 8). The results
mentioned above indicated that an efficient antigen-spe-
cific T cell activation, most probably CD8
+ T cells, was
induced by ORFV DNA vaccine plasmids expressing the
MHC class I epitope.
Figure 3 Group mean optical density ratios and standard errors for specific anti-ORFV-IgG antibody responses in the serum samples
of immunized mice of different groups. The sera were collected from mice in groups (pcDNA3.1-ORFV011 group, pcDNA3.1-ORFV059 group,
pcDNA3.1-ORFV011/ORFV059 group, pcDNA3.1-ORFV 011 plus pcDNA3.1-ORFV059 group, pcDNA3.1(+) group and PBS group) at weeks 0, 1, 2, 3,
4, 5, 6, 7, 8 and were inactivated at 56° for 30 min. The ORFV-specific antibody responses were determined using an indirect ELISA, with the
purified ORFV as the coating antigen. As shown in Figure 3, the levels of anti-ORFV-IgG antibodies were developed in different DNA vaccine
plasmid- immunized group. One week after the final boost immunization, the level of anti-ORFV-IgG antibodies was higher in the pcDNA3.1-
ORFV 011/ORFV 059 immunized group than any of the other groups tested (OD450 value: 0.829 ± 0.014, **P < 0.01). The levels of anti-ORFV-IgG
antibodies in both of pcDNA3.1-ORFV 011 group and pcDNA3.1-ORFV 059 group were very nearly, but in the pcDNA3.1-ORFV 011 group
increased slightly compared with the pcDNA3.1-ORFV 059 group (OD450 value: 0.579 ± 0.009 vs 0.518 ± 0.003, P > 0.05). The levels of anti-ORFV-
IgG antibodies was higher in the pcDNA3.1-ORFV 011/ORFV 059 group than pcDNA3.1-ORFV 011 plus pcDNA3.1-ORFV 059 group (OD450 value:
0.829 ± 0.014 vs 0.687 ± 0.024, *P < 0.05). A group: PBS; B group: pcDNA3.1(+) vector; C group: pcDNA3.1-ORFV011; D group: pcDNA3.1-
ORFV059; E group: pcDNA3.1-ORFV011 plus pcDNA3.1-ORFV059; F group: pcDNA3.1-ORFV011/ORFV059.
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T h ec o n t i n u i n go c c u r r e n c eo fO r fi nt h eo v i n ea n d
caprine herds all over the world emphasizes the need to
develop novel vaccines with improved properties com-
pared to the currently used attenuated live vaccines.
One promising approach is the use of viral DNA vac-
cines because they are safe and can induce both neutra-
lizing antibodies and cellular immune responses while
maintaining the advantages of subunit and traditional
vaccines [22,23]. To our knowledge, the current study is
the first report demonstrating the potential of an ORFV
DNA vaccine to induce strong immune responses in
mice.
ORFV 011 and ORFV 059 are two major immunodo-
minant proteins which have been demonstrated to
induce a strong humoral response against ORFV [17,24].
In our study, ORFV DNA vaccines can induced specific
humoral and cellular responses in mice. The levels of
ORFV-specific IgG antibodies were greatly enhanced fol-
lowing two boosts. In addition, the higher neutralizing
antibodies were detected in pcDNA3.1-ORFV 059,
pcDNA3.1-ORFV 011 plus pcDNA3.1-ORFV 059 or
pcDNA3.1-ORFV 011/ORFV 059 groups. Our findings
are supported by a previous study showing that ORFV
059 protein could induce the production of neutralizing
antibodies [15]. The measurement of certain antibody
isotypes correlates directly to type 1 or type 2 T cell
responses [25]. For example, IgG2a in mice [26] is asso-
ciated with in vivo production of IFN-g and can be used
as an indicator to measure the type 1 responses. Here,
the IgG2a:IgG1 isotypes in immunized mice were
assayed by ELISA. The levels of anti-ORFV IgG1 and
IgG2a in DNA vaccine plasmids immunizations groups
were higher than control groups. We further examined
whether there was any difference in the type of T helper
responses among these groups by using the IgG2a/IgG1
ratio as a surrogate marker. Interestingly, the ratios of
IgG2a/IgG1 in mice receiving DNA vaccine plasmids
immunizations were more than 1, indicating that DNA
vaccine plasmid constructs induced predominantly a
Th1-type immune response after the final boost
immunization.
Next, T-cell immune responses were also observed in
our study. T lymphocytes are generally divided into
Figure 4 The subclasses IgG1 and IgG2a of anti-ORFV IgG antibodies in the serum samples of immunized mice of different groups.
Sera were taken from immunized mice of different groups 1 week post the final boost immunization. The titration of ORFV-specific
immunoglobulin (IgG) subclasses 1 and 2a was detected by ELISA. As shown in Figure 4, the assay of IgG2a and IgG1 antibodies performed at 1
week post the final boost immunization indicates a significant difference between vaccine plasmids groups (including pcDNA 3.1-ORFV011
group, pcDNA 3.1-ORFV059 group, pcDNA3.1-ORFV011 plus pcDNA3.1-ORFV059 group and pcDNA3.1-ORFV011/ORFV059 group) and control
groups (including PBS and pcDNA3.1(+) group) (**P < 0.01). A group: PBS; B group: pcDNA3.1(+) vector; C group: pcDNA3.1-ORFV011; D group:
pcDNA3.1-ORFV059; E group: pcDNA3.1-ORFV011 plus pcDNA3.1-ORFV059; F group: pcDNA3.1-ORFV011/ORFV059.
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2 weeks post immunization. The sera (diluted 1:5 in MEM medium) were heat-activated for 30 min at 56°C, then serially diluted two-fold in 96-
well flat bottom plates and incubated with 0.1 μg of purified ORFV diluted in 50 μl MEM for 90 min at 37°C. All sera were run in triplicate.
Subsequently, 100 μl of OFTu cell suspension were added to each well at a concentration of 45,000 cells/well. The plates were incubated for 5
days at 37°C in a 5% CO2 incubator. The titer is expressed as ND50 and calculated using the Reed and Muench method. As shown in Figure 5,
the assay of virus-neutralizing titers performed at 2 weeks post immunization indicates a significant difference between four vaccine plasmids
groups (including pcDNA 3.1-ORFV 011 group, pcDNA 3.1-ORFV 059 group, pcDNA-ORFV 011 plus pcDNA-ORFV 059 group and pcDNA-ORFV
011/ORFV 059 group) and control groups (including PBS and pcDNA3.1(+) group) (**P < 0.01). Among the four vaccine plasmids groups, the
virus-neutralizing titers in the pcDNA-ORFV 011/ORFV 059 group was significantly higher than that of pcDNA-ORFV 011 plus pcDNA-ORFV 059
group (*P < 0.05). A group: PBS; B group: pcDNA3.1(+) vector; C group: pcDNA3.1-ORFV011; D group: pcDNA3.1-ORFV059; E group: pcDNA3.1-
ORFV011 plus pcDNA3.1-ORFV059; F group: pcDNA3.1-ORFV011/ORFV059.
Figure 6 Proliferation of spleen lymphocytes in the different groups. Six groups of 6-8-week-old female Balb/c mice were immunized by
skin scarification with one of the following formulations: (A) PBS; (B) pcDNA3.1(+) vector; (C) pcDNA3.1-ORFV011; (D) pcDNA3.1-ORFV059; (E)
pcDNA3.1-ORFV011 plus pcDNA3.1-ORFV059; (F) pcDNA3.1-ORFV011/ORFV059. Each bar represents the group mean (N = 10) ± S.E.M. of SI
determined in triplicate. The mitogen, Con A served as a positive antigen and positive control. As shown in Figure 5, mice immunized with
pcDNA3.1-ORFV011/ORFV059 (F group) induced a stronger proliferation response compared with background OD (0.281 ± 0.123) (**P < 0.01).
The E group, immunized with pcDNA3.1-ORFV011 plus pcDNA3.1-ORFV059, also resulted displayed a higher stimulation index (SI) than mice
immunized with PBS, pcDNA3.1 (+) or vaccine plasmid alone. However, the stimulation index (SI) in pcDNA3.1-ORFV011/ORFV059 group
increased slightly compared with the pcDNA3.1-ORFV011 plus pcDNA3.1-ORFV059 group (P > 0.05), and the stimulation index (SI) were no
obvious difference between pcDNA3.1-ORFV 011 group and pcDNA3.1-ORFV 059 group (P > 0.05).
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Page 9 of 12helper (CD4
+)a n dC T L( C D 8
+) cells. CD4
+ T cells can
increase the number of memory cells. The memory cells
respond rapidly when re-exposed to pathogens and thus
play a vital role in protection against viral challenge
[27,28]. After activation, naive antigen-specific CD8
+ T
cells are able to proliferate quickly and differentiate into
potent effector cells capable of rapid cytokine produc-
tion and cytolytic killing of target cells [29]. CD4
+ lym-
phocytes are further subdivided into Th1 and Th2 on
the basis of the type of released cytokines. The Th1 cell
subset mainly includes cells secreting IL-2, TNF-a,a n d
INF-g. The main roles of these cytokines include enhan-
cing killer cell cytotoxicity and cell-mediated immune
response. The Th2 cell subset mainly includes cells pro-
ducing IL-4, IL-6, and IL-10. The role of Th2 cytokines
is to promote antibody production and mediate humoral
immune response. In the study, we investigated the
responsiveness of spleen cells from immunized mice
against ORFV. The levels of cytokines production (IFN-
g,T N F - a, IL-2, IL-4 and IL-6) in the supernatant of
splenocytes stimulated with purified ORFV were deter-
mined by ELISA assay. The levels of IFN-g,T N F - a and
IL-2 produced by splenocytes immunized with ORFV
DNA vaccine plasmids were significantly higher than
that with pcDNA3.1 (+) or PBS (**P < 0.01). The result
indicated that an efficient antigen-specific T cell activa-
tion, most probably CD8
+ T cells, was induced by
ORFV DNA vaccine plasmids expressing the MHC class
I epitope.
To further address the T cell response, we examined
the CD4
+ and CD8
+ splenocytes collected from immu-
nized mice by flow cytometry analysis. The percentages
of CD4
+ and CD8
+ cells in mice immunized with DNA
vaccine plasmids increased significantly compared to
Figure 7 The CD4
+ and CD8
+ T lymphocyte subsets in the different groups were assessed by FACS analysis at day 10 post the final
boost immunization. Spleen lymphocytes of mice in different immunized groups were repectively enriched from the spleens at days 10 post
the final boost immunization and cultured in RPMI 1640 medium. The CD4
+ and CD8
+ T lymphocyte subsets in the different groups were
assessed by FACS in order to examine whether or not DNA vaccine constructs immunized mice by skin scarification can induce a T-cell response
in mice and further activate cell immunity response. (A) PBS; (B) pcDNA3.1(+) vector; (C) pcDNA3.1-ORFV011; (D) pcDNA3.1-ORFV059; (E)
pcDNA3.1-ORFV011 plus pcDNA3.1-ORFV059; (F) pcDNA3.1-ORFV011/ORFV059.
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ratios of CD4
+/CD8
+ cells in mice immunized with vac-
cine plasmids were higher than the control groups.
These results further indicate that the DNA vaccine
constructs can induce a T-cell response in mice and
activate cell immunity response.
Taken together, these data indicate that in vaccinated
mice, the ORFV011 and ORFV059 can be expressed and
secreted, induce specific humoral and cellular immune
responses by activate both B and T cells, and the chi-
meric expression of ORFV011 and ORFV059 could sig-
nificantly improve the potency of DNA vaccination. We
concluded that DNA vaccine pcDNA3.1-ORFV011/
ORFV059 expressing ORFV011 and ORFV059 che-
meric-proteins can significantly improve the potency of
DNA vaccination and could be served as more effective
and safe approach for new vaccines against ORFV.
Further studies are being carried out in lambs to under-
stand the similarities and differences in the response
between mice and lambs. These studies will provide a
basis for the development of an ORFV DNA vaccine
ready for clinical trial.
Conclusions
We concluded that DNA vaccine pcDNA3.1-ORFV011/
ORFV059 expressing ORFV011 and ORFV059 che-
meric-proteins can significantly improve the potency of
DNA vaccination and could be served as more effective
and safe approach for new vaccines against ORFV.
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Figure 8 The production of ORFV-specific cytokines in the supernatant of splenocytes stimulated with purified ORFV at day 10 post the
final boost immunization. Six groups of of 6-8-week-old female Balb/c mice were immunized by skin scarification with one of the following
formulations: (A) PBS; (B) pcDNA3.1(+) vector; (C) pcDNA3.1-ORFV011; (D) pcDNA3.1-ORFV059; (E) pcDNA3.1-ORFV011 plus pcDNA3.1-ORFV059; (F)
pcDNA3.1-ORFV011/ORFV059. The levels of cytokines production (IFN-g,T N F - a, IL-2, IL-4 and IL-6) in the supernatant of splenocytes stimulated with
purified ORFV were determined by ELISA assay. Each bar represents the group mean (N = 10) ± S.E.M. of cytokines levels determined in triplicate.
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